top of page

Ketamine and Postpartum Depression: A Promising New Treatment Option

  • Alexander Papp, MD
  • Dec 1, 2024
  • 3 min read

Updated: 3 days ago


A new study published in The British Medical Journal looked into whether giving a single low dose of ketamine (in the form of esketamine) right after childbirth could help reduce postpartum depression in mothers who were depressed during pregnancy.


How the Study Was Conducted

This was a well-designed randomized, placebo-controlled, double-blind trial—in plain English, doctors didn’t know who was getting esketamine and who was getting a look-alike (placebo), and neither did the participants. The trial ran across five hospitals in China between mid-2020 and summer 2022. They selected women who had prenatal depression (scoring high enough on standardized scales) but didn’t have certain high-risk medical issues. Esketamine (0.2 mg/kg) was given intravenously within 40 minutes of childbirth, just after the baby was born and the cord was clamped.


Key Findings

Here’s the striking part: by day 42 after giving birth, only 6.7% of the moms in the esketamine group experienced a major depressive episode—compared with 25% in the placebo group. That’s roughly a three-quarter reduction in new depressive episodes—and that’s with just one dose right after delivery.


Mood scales tell the same story. On top of that headline figure, the mothers who got esketamine scored better on standard depression scales. Their Edinburgh Postnatal Depression Scale (EPDS) scores were several points lower at day 7 and day 42. Their Hamilton Depression Rating Scale (HDRS) scores were also notably improved by day 42—by about 4 points, which is clinically meaningful.


The side effect were short-lived and manageable. About 45%of esketamine-treated mothers reported temporary symptoms like dizziness, blurred vision, or mild hallucinations, versus about 22% in the placebo group. Reassuringly, all these effects disappeared within 24 hours and didn’t require any medication to resolve.


So What’s the Takeaway?

This study offers real hope—showing that a single, carefully dosed treatment with with ketamine (or esketamine) right after delivery could substantially lower the risk of postpartum depression in mothers who were already struggling during pregnancy. Importantly, it worked fast and lasted at least six weeks. Of course, it was done under controlled conditions—timing, dosage, and monitoring were precise. This treatment isn’t something an outpatient psychiatric clinic can provide, but if you’re pregnant and have a history of depression, it’s worth discussing this option with your hospital care team before delivery. And yes—this is exciting, life-affirming potential on the horizon.


The Science Behind Ketamine and Postpartum Depression 

Postpartum depression (PPD) affects approximately 1 in 7 mothers in the United States, yet remains undertreated due to stigma, lack of access, and delays in diagnosis (ACOG, 2023). The emergence of peripartum ketamine administration as a prophylactic intervention represents a meaningful advancement in perinatal psychiatry. Unlike traditional antidepressants, which may take weeks to reach therapeutic efficacy, esketamine's glutamatergic mechanism of action—specifically its antagonism of NMDA receptors—is associated with rapid neuroplastic changes that may confer early and sustained mood stabilization (Zanos & Gould, 2018).


References:

____________________

Alexander Papp, MD

Comments

Rated 0 out of 5 stars.
No ratings yet
Add a rating
bottom of page